

Freedom of Information request 015171

11/2/2020

- Does a specific venous thromboembolism protocol exist for your Trust - Yes

If so:

- What date was this protocol put into place : December 20th 2016

- When is it due for review? - currently being reviewed. Further pathway published Dec 2019 for Deep Vein Thrombosis pathway (Suspected Deep Vein Thrombosis Pathway and subsequent Management for Ambulatory Adults)

- Is there a preferred Direct Oral Anticoagulant (DOAC) or are all utilised within the trust for VTE:
- Preferred DOAC is Rivaroxaban, however following success of management of change in newer anticoagulants other DOACs used only after discussion with haematology consultant, and is listed for discussion in the next trust thrombosis group meeting to expand.

- How many patients have been treated for VTE with a DOAC in the last 12 months

- What volume of each DOAC was used to Treat VTE in this same time period

See report below - report run from 1/2/2019 to 1/2/20 - Some patients may have been captured twice if change of drug

Abbreviations from the attached report in full	Cerebral Venous SinusThrombosis
DVTP	Deep Vein Thrombosis
DVTU	Deep Vein Thrombosis unprovoked
PE Provoked	Pulmonary Embolism provoked
PE Unprovoked	Pulmonary Embolism unprovoked
PE whilst Anticoagulated	Pulmonary Embolism whilst Anticoagulated
	Portal Vein Thrombosis
Recurrent DVT	Recurrent Deep Vein Thrombosis
Recurrent VTE	Recurrent venousthromboembolism
VTE	Venousthromboembolism

11/02/2020

AC Drug Patient Summary - Diagnosis and Drug

Episode Start Date Range: 01/02/2019 To 01/02/2020

Total Patients: 720

Cerebral Venous SinusThrombosi Patients: 10

Apixiban 5mg	1
LMWH	1
Warfarin 1mg	1
Warfarin 3mg	7

DVTP Patients: 217

Apixiban 5mg	14
Apixaban 2.5mg	4
Dab 110	5
Dalt 10000	4
Dalt 12500	12
Dalt 15000	13
Dalt 18000	17
Dalt 5000	1
Dalt 7500	1
DOAC	3
LMWH	12
Riva 10	2
RIVA 15 BD	13
Riva 20	118
Warfarin 3mg	13

DVTU Patients: 155

Apixiban 5mg	10
Apixaban 2.5mg	3
Dab 110	1
Dalt 7500	1
Dalt 7500BD	1
LMWH	3
Riva 10	6
RIVA 15 BD	6
Riva 20	113
Warfarin 1mg	2
Warfarin 3mg	18

PE Provoked	Patients: 145
--------------------	----------------------

Apixiban 5mg	10
Apixiban 2.5mg	2
Dalt 10000	7

11/02/2020

AC Drug Patient Summary - Diagnosis and Drug

Episode Start Date Range: 01/02/2019 To 01/02/2020

Total Patients: 720

Dalt 12500	9
Dalt 15000	12
Dalt 18000	17
Dalt 5000	2
Dalt 7500BD	1
DOAC	2
LMWH	17
Riva 10	1
Riva 20	62
Warfarin 1mg	1
Warfarin 3mg	5

PE Unprovoked	Patients: 157
----------------------	----------------------

Apixiban 5mg	17
Apixiban 2.5mg	1
Dab 110	1
Dab 150	1
Dalt 10000	1
Dalt 15000	2
Dalt 18000	3
Dalt 7500	2
LMWH	1
Riva 10	13
RIVA 15 BD	6
Riva 20	109
Warfarin 1mg	1
Warfarin 3mg	18

PE whilst Anticoagulated	Patients: 2
---------------------------------	--------------------

Dalt 15000	1
------------	---

Warfarin 3mg	1
--------------	---

Portal Vein Thrombosis	Patients: 7
-------------------------------	--------------------

Dalt 15000	1
------------	---

Dalt 7500	3
-----------	---

LMWH	1
------	---

Riva 20	2
---------	---

Recurrent DVT	Patients: 1
----------------------	--------------------

Warfarin 3mg	1
--------------	---

Recurrent VTE	Patients: 2
----------------------	--------------------

Riva 20	1
---------	---

Warfarin 3mg	1
--------------	---

VTE	Patients: 29
------------	---------------------

Apaxiban 5mg	1
--------------	---

Dalt 10000	3
------------	---

Dalt 12500	3
------------	---

Dalt 15000	1
------------	---

Dalt 18000	2
------------	---

LMWH	2
------	---

Riva 20	8
---------	---

Warfarin 1mg	2
--------------	---

Warfarin 3mg	7
--------------	---